| Tracking the evolution of non–small-cell lung cancer M Jamal-Hanjani, GA Wilson, N McGranahan, NJ Birkbak, TBK Watkins, ... New England Journal of Medicine 376 (22), 2109-2121, 2017 | 2236 | 2017 |
| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ... Nature 545 (7655), 446-451, 2017 | 1726 | 2017 |
| Small-cell lung cancer JP Van Meerbeeck, DA Fennell, DKM De Ruysscher The Lancet 378 (9804), 1741-1755, 2011 | 1229 | 2011 |
| Allele-specific HLA loss and immune escape in lung cancer evolution N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ... Cell 171 (6), 1259-1271. e11, 2017 | 1195 | 2017 |
| Fc effector function contributes to the activity of human anti-CTLA-4 antibodies FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ... Cancer cell 33 (4), 649-663. e4, 2018 | 552 | 2018 |
| Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer B Delage, DA Fennell, L Nicholson, I McNeish, NR Lemoine, T Crook, ... International journal of cancer 126 (12), 2762-2772, 2010 | 445 | 2010 |
| Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled … M Maio, A Scherpereel, L Calabrò, J Aerts, SC Perez, A Bearz, ... The Lancet Oncology 18 (9), 1261-1273, 2017 | 435 | 2017 |
| Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ... Immunity 46 (4), 577-586, 2017 | 422 | 2017 |
| Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer DA Fennell, Y Summers, J Cadranel, T Benepal, DC Christoph, R Lal, ... Cancer treatment reviews 44, 42-50, 2016 | 366 | 2016 |
| Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up P Baas, D Fennell, KM Kerr, PE Van Schil, RL Haas, S Peters Annals of oncology 26, v31-v39, 2015 | 366 | 2015 |
| MicroRNA regulation of core apoptosis pathways in cancer RT Lima, S Busacca, GM Almeida, G Gaudino, DA Fennell, ... European journal of cancer 47 (2), 163-174, 2011 | 341 | 2011 |
| Novel insights into mesothelioma biology and implications for therapy TA Yap, JG Aerts, S Popat, DA Fennell Nature Reviews Cancer 17 (8), 475-488, 2017 | 337 | 2017 |
| Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature MP Barr, SG Gray, AC Hoffmann, RA Hilger, J Thomale, JD O’Flaherty, ... PloS one 8 (1), e54193, 2013 | 317 | 2013 |
| Tracking genomic cancer evolution for precision medicine: the lung TRACERx study M Jamal-Hanjani, A Hackshaw, Y Ngai, J Shaw, C Dive, S Quezada, ... PLoS biology 12 (7), e1001906, 2014 | 310 | 2014 |
| The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC C Manegold, AMC Dingemans, JE Gray, K Nakagawa, M Nicolson, ... Journal of Thoracic Oncology 12 (2), 194-207, 2017 | 233 | 2017 |
| In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion PW Szlosarek, A Klabatsa, A Pallaska, M Sheaff, P Smith, T Crook, ... Clinical cancer research 12 (23), 7126-7131, 2006 | 228 | 2006 |
| ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma A Scherpereel, I Opitz, T Berghmans, I Psallidas, M Glatzer, D Rigau, ... European respiratory journal 55 (6), 2020 | 218 | 2020 |
| Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial DA Fennell, S Ewings, C Ottensmeier, R Califano, GG Hanna, K Hill, ... The Lancet Oncology 22 (11), 1530-1540, 2021 | 214* | 2021 |
| Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo … LM Krug, HL Kindler, H Calvert, C Manegold, AS Tsao, D Fennell, ... The Lancet Oncology 16 (4), 447-456, 2015 | 213 | 2015 |
| British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma I Woolhouse, L Bishop, L Darlison, D De Fonseka, A Edey, J Edwards, ... Thorax 73 (Suppl 1), i1-i30, 2018 | 211 | 2018 |
